Jonatan D Lindh

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. doi request reprint Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis
    Jonatan D Lindh
    Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Eur J Clin Pharmacol 65:365-75. 2009
  2. ncbi request reprint Several-fold increase in risk of overanticoagulation by CYP2C9 mutations
    Jonatan D Lindh
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Institute of Environmental Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, S 141 86 Stockholm, Sweden
    Clin Pharmacol Ther 78:540-50. 2005
  3. ncbi request reprint Incidence and predictors of severe bleeding during warfarin treatment
    Jonatan D Lindh
    Division of Clinical Pharmacology, C1 68, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden
    J Thromb Thrombolysis 25:151-9. 2008
  4. doi request reprint A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele
    Marine L Andersson
    Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Pharmacogenomics 13:757-62. 2012
  5. pmc Internet based clinical trial protocols -- as applied to a study of warfarin pharmacogenetics
    Jonatan D Lindh
    Division of Clinical Pharmacology, Karolinksa University Hospital Huddinge, Stockholm, Sweden
    Br J Clin Pharmacol 58:482-7. 2004
  6. doi request reprint CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients
    Sara Margolin
    Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics 14:613-22. 2013
  7. doi request reprint Therapeutic drug monitoring for tomorrow
    Erik Eliasson
    Karolinska University Laboratory, Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden
    Eur J Clin Pharmacol 69:25-32. 2013
  8. doi request reprint Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study
    Linda Björkhem-Bergman
    Karolinska Institutet, Department of Laboratory Medicine, Divisions of Clinical Pharmacology, Stockholm, Sweden
    Drug Metab Dispos 41:704-8. 2013
  9. ncbi request reprint Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome
    Georgios Panagiotidis
    Department of Laboratory Medicine, Division of Clinical Pharmacology, CI 68 Karolinska University Hospital, SE 141 86 Stockholm, Sweden
    Ther Drug Monit 29:417-22. 2007
  10. doi request reprint Vitamin D and drug-metabolising enzymes
    Jonatan D Lindh
    Karolinska Institutet, Department of Laboratory Medicine, Clinical Pharmacology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Photochem Photobiol Sci 11:1797-801. 2012

Detail Information

Publications21

  1. doi request reprint Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis
    Jonatan D Lindh
    Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Eur J Clin Pharmacol 65:365-75. 2009
    ..To quantify the influence of common cytochrome P450 2C9 (CYP2C9) polymorphisms on warfarin dose requirements...
  2. ncbi request reprint Several-fold increase in risk of overanticoagulation by CYP2C9 mutations
    Jonatan D Lindh
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Institute of Environmental Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, S 141 86 Stockholm, Sweden
    Clin Pharmacol Ther 78:540-50. 2005
    ..Our objective was to prospectively study the impact of CYP2C9 polymorphism (*2 and *3) on the risk of overanticoagulation during the induction phase of warfarin therapy...
  3. ncbi request reprint Incidence and predictors of severe bleeding during warfarin treatment
    Jonatan D Lindh
    Division of Clinical Pharmacology, C1 68, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden
    J Thromb Thrombolysis 25:151-9. 2008
    ..This variation may be caused by time trends, variation in bleeding definition and study subject selection. We investigated the incidence of, and risk factors for severe bleeding in un-selected warfarin-treated patients from Sweden...
  4. doi request reprint A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele
    Marine L Andersson
    Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Pharmacogenomics 13:757-62. 2012
    ..Simvastatin interacts with warfarin, but the strength of the interaction varies between individual patients, indicating a genetic predisposition...
  5. pmc Internet based clinical trial protocols -- as applied to a study of warfarin pharmacogenetics
    Jonatan D Lindh
    Division of Clinical Pharmacology, Karolinksa University Hospital Huddinge, Stockholm, Sweden
    Br J Clin Pharmacol 58:482-7. 2004
    ..To describe and evaluate the use of an Internet-based study protocol in a multicentre study of genetic risk factors in anticoagulant treatment...
  6. doi request reprint CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients
    Sara Margolin
    Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics 14:613-22. 2013
    ..We analyzed the impact of the CYP2D6 polymorphism in pre- and post-menopausal patients that were adherent to tamoxifen treatment for at least a year...
  7. doi request reprint Therapeutic drug monitoring for tomorrow
    Erik Eliasson
    Karolinska University Laboratory, Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden
    Eur J Clin Pharmacol 69:25-32. 2013
    ....
  8. doi request reprint Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study
    Linda Björkhem-Bergman
    Karolinska Institutet, Department of Laboratory Medicine, Divisions of Clinical Pharmacology, Stockholm, Sweden
    Drug Metab Dispos 41:704-8. 2013
    ....
  9. ncbi request reprint Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome
    Georgios Panagiotidis
    Department of Laboratory Medicine, Division of Clinical Pharmacology, CI 68 Karolinska University Hospital, SE 141 86 Stockholm, Sweden
    Ther Drug Monit 29:417-22. 2007
    ..A model to predict plasma concentration from dose and number of active CYP2D6 alleles was formed from the obtained data by means of multiple linear regression...
  10. doi request reprint Vitamin D and drug-metabolising enzymes
    Jonatan D Lindh
    Karolinska Institutet, Department of Laboratory Medicine, Clinical Pharmacology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Photochem Photobiol Sci 11:1797-801. 2012
    ..Taken together, vitamin D status might contribute to inter- and intraindividual differences in drug metabolism, but the therapeutic impact of these findings remains to be established...
  11. pmc Possible drug-drug interaction between quetiapine and lamotrigine--evidence from a Swedish TDM database
    Marine L Andersson
    Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge, Karolinska Institutet, 141 86 Stockholm, Sweden
    Br J Clin Pharmacol 72:153-6. 2011
    ..The aim of the present study was to investigate a previously proposed interaction between quetiapine and lamotrigine resulting in reduced serum quetiapine concentrations...
  12. ncbi request reprint Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine
    Jonatan D Lindh
    Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden
    Eur J Clin Pharmacol 59:401-6. 2003
    ..To study the influence of CYP3A4 inhibition by ketoconazole on the disposition of venlafaxine in individuals with different CYP2D6 pheno- and genotypes...
  13. doi request reprint Influence of the CYP2C9*3 allele on the pharmacological interaction between warfarin and simvastatin: author reply
    Marine L Andersson
    Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Pharmacogenomics 13:1561-2. 2012
    ..A letter in response to: Botton MR, Hutz MA & Suarez-Kurtz G. Influence of the CYP2C9*3 allele on the pharmacological interaction between warfarin and simvastatin. Pharmacogenomics 13(14), 1557-1559 (2012)...
  14. doi request reprint Seasonal variation in blood drug concentrations and a potential relationship to vitamin D
    Jonatan D Lindh
    Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge, SE 141 86 Stockholm, Sweden
    Drug Metab Dispos 39:933-7. 2011
    ..Even though a causal relationship remains to be established, it is suggested that individual differences in vitamin D may contribute to variability in drug metabolism and disposition...
  15. ncbi request reprint Direct and efficient liquid chromatographic-tandem mass spectrometric method for opiates in urine drug testing - importance of 6-acetylmorphine and reduction of analytes
    Maria Andersson
    Division of Clinical Pharmacology, Karolinska Institute and University Hospital, Stockholm, Sweden
    Drug Test Anal 6:317-24. 2014
    ..The method might be further developed by reducing the number of analytes to morphine-3-glucuronide, codeine-6-glucuronide and 6-acetylmorphine without compromising test performance. Copyright © 2013 John Wiley & Sons, Ltd. ..
  16. ncbi request reprint Adherence to guidelines for avoiding drug interactions associated with warfarin--a Nationwide Swedish Register Stud
    Jonatan D Lindh
    Dept of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 9:e97388. 2014
    ..We hypothesised that clinicians would avoid combining non-steroidal anti-inflammatory drugs (NSAIDs), tramadol and sulfamethoxazole with warfarin...
  17. pmc Pharmacogenetics of anticoagulants
    Anders Rane
    Division of Clinical Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden
    Hum Genomics Proteomics 2010:754919. 2010
    ..Application of these measures in the care of patients with anticoagulant therapy is important awaiting new therapeutic principles to be introduced, which may take long time still...
  18. doi request reprint Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis
    Linda Björkhem-Bergman
    Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge, Karolinska Institutet, 141 86 Stockholm, Sweden
    J Psychopharmacol 25:299-305. 2011
    ..However, metformin is not approved for use in non-diabetic patients and it is still not generally advisable to recommend metformin to counteract antipsychotic-induced weight gain...
  19. ncbi request reprint Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene
    Karin Hedenmalm
    Drug Epidemiology Unit, Medical Products Agency, 75103 Uppsala, Sweden
    Eur J Clin Pharmacol 60:369-72. 2004
    ..This study aimed to investigate the importance of cytochrome P(450) enzymes for the reported interaction between tramadol and warfarin...
  20. ncbi request reprint Comment: patient-specific factors predictive of warfarin dosage requirements
    Jonatan D Lindh
    Ann Pharmacother 37:454; author reply 454. 2003